RGEN - 2 Reasons to Buy Repligen and 1 Reason to Sell
Much has been written about the life sciences industry in the wake of COVID-19. The bottom line is that the bar for speed of innovation, regulation, and collaboration has been forever raised.
With a renewed interest in science, the companies behind the research and development process should experience a golden age over the next few years and beyond. Repligen (NASDAQ: RGEN) -- a provider of bioprocessing systems -- is trying to step front and center.
The company has used many small acquisitions over the past few years to piece together impressive growth. But could the risks be growing? Here are two good reasons to buy the stock and one possible reason to sell.
For further details see:
2 Reasons to Buy Repligen, and 1 Reason to Sell